- Home
- TAC vs VKTX Comparison
TAC vs VKTX Comparison
Compare TAC & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAC
- VKTX
- Stock Information
- Founded
- TAC 1909
- VKTX 2012
- Country
- TAC Canada
- VKTX United States
- Employees
- TAC N/A
- VKTX N/A
- Industry
- TAC Electric Utilities: Central
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- TAC Utilities
- VKTX Health Care
- Exchange
- TAC Nasdaq
- VKTX Nasdaq
- Market Cap
- TAC 2.9B
- VKTX 2.8B
- IPO Year
- TAC N/A
- VKTX 2015
- Fundamental
- Price
- TAC $10.74
- VKTX $26.67
- Analyst Decision
- TAC Buy
- VKTX Buy
- Analyst Count
- TAC 2
- VKTX 12
- Target Price
- TAC $19.75
- VKTX $84.00
- AVG Volume (30 Days)
- TAC 1.8M
- VKTX 3.8M
- Earning Date
- TAC 07-31-2025
- VKTX 07-23-2025
- Dividend Yield
- TAC 1.64%
- VKTX N/A
- EPS Growth
- TAC N/A
- VKTX N/A
- EPS
- TAC 0.00
- VKTX N/A
- Revenue
- TAC $1,847,844,992.00
- VKTX N/A
- Revenue This Year
- TAC N/A
- VKTX N/A
- Revenue Next Year
- TAC N/A
- VKTX N/A
- P/E Ratio
- TAC $4,629.63
- VKTX N/A
- Revenue Growth
- TAC N/A
- VKTX N/A
- 52 Week Low
- TAC $6.78
- VKTX $18.92
- 52 Week High
- TAC $14.64
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- TAC 56.88
- VKTX 48.50
- Support Level
- TAC $10.56
- VKTX $26.20
- Resistance Level
- TAC $10.91
- VKTX $28.20
- Average True Range (ATR)
- TAC 0.32
- VKTX 1.61
- MACD
- TAC -0.09
- VKTX -0.03
- Stochastic Oscillator
- TAC 38.33
- VKTX 45.05
About TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse and growing fleet of electrical power generation assets in Canada, the United States, and Australia. The company has six reportable segments namely, Hydro, Wind & Solar, Energy Marketing, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.